The North America late-stage chronic kidney disease drugs market is expected to reach US$ 4,904.81 million by 2027 from US$ 2,036.47 million in 2019; it is estimated to grow at a CAGR of 11.8% from 2020 to 2027.
The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the key factors driving the market growth in this region. However, delay in the diagnosis of chronic kidney diseases hampers the market growth.
In late-stage renal disease, kidneys lose their ability to filter waste and excess fluid from blood, which leads to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. According to the Centers for Disease Control and Prevention(CDC), in 2014, ~118,000 people in the US began taking treatment for end-stage renal disease, and the number is expected to increase in the coming years with surging awareness regarding this condition. These factors are expected to enhance market growth during the forecast period. Also, various strategies put forth by the World Health Organisation (WHO) to support policymakers in developing suitable policies, entailing the vital medicine list concept and the universal health coverage (UHC) approach,would boost the market growth in the coming years.
The COVID-19 pandemic has negatively impacted North America's late-stage chronic kidney disease drugs market. Elderly people and kidney disease patients seem to be at higher risk for more serious COVID-19 illness. However, Nephrology societies have made suggestions and provided guidelines to prevent COVID-19 transmission in dialysis facilities and to provide emergency services for patients. Therefore, the late-stage chronic kidney disease drugs market is expected to regain traction in the coming months.
Based on product type, the North America late-stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the largest share of the market in 2019, and it is expected to register the highest CAGR during the forecast period.
The North Americalate stage chronic kidney disease drugs market, based on Indication, is segmented into late stage chronic kidney disease induced hyperparathyroidism, late stage chronic kidney disease induced hyperphosphatemia, and late stage chronic kidney disease induced hyperkalemia. The late-stage chronic kidney disease induced hyperparathyroidism segment held the largest market share in 2019, and it is estimated to register the highest CAGR during 2020–2027.
Based on distribution channel, the North America late-stage chronic kidney disease drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospital pharmacies segment held the largest share of the market in 2019. However, the market for the online pharmacies segment is estimated to growat the highest CAGR during the forecast period.
A few of the primary and secondary sources associated with this report on the North America late-stage chronic kidney disease drugs market are the American Cancer Society (ACR),Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH).